Concepedia
Statistics
Publications
26
Citations
2.5K
H-Index
21
Active since
1955
Affiliations
Deciphera Pharmaceuticals (United States)(Current)
Tufts Medical Center
The University of Texas MD Anderson Cancer Center
National Cancer Institute
Oregon Health & Science University
Scott Wise is an author at Deciphera Pharmaceuticals (United States) specializing in pharmacology, medicine, and oncology.
Publications per year
1955–2022
Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers
Sheng-Bin Peng, James R. Henry, Michael D. Kaufman et al. · Cancer Cell · 2015 · 309 citations · Full text
Medicine, Cancer Biology, Oncology +16
Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants
Bryan D. Smith, Michael D. Kaufman, Wei-Ping Lu et al. · Cancer Cell · 2019 · 277 citations
Medicine, Oncology, Pharmacology +17
Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone.
Heidi S. Camp, O Li, Scott Wise et al. · Diabetes · 2000 · 223 citations · Full text
Medicine, Molecular Biology, Pharmacology +17
cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype
Leia M. Smith, Scott Wise, Denver T. Hendricks et al. · Oncogene · 1999 · 213 citations
Medicine, Cancer Biology, Oncology +11
Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036
Wayne W. Chan, Scott Wise, Michael D. Kaufman et al. · Cancer Cell · 2011 · 207 citations · Full text
Life Sciences, Biochemistry, Molecular Biology +14
1–5 of 26